Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema

Seminars in Ophthalmology

Volumn 24, Issue 6, 2009, Pages 225-230

  Tsilimbaris, Miltiadis K ^a   Pandeleondidis, Vassilios ^a   Panagiototglou, Theoni ^a   Arvanitaki, Vassiliki ^a   Fragiskou, Sofia ^a   Eleftheriadou, Maria ^a   Tsika, Chrysanthi ^a   Papadaki, Theokliti ^a  

^a Heraklion University   (Greece)

Author keywords

Anti VEGF; Combination therapy; Diabetic maculopathy; Intravitreal injections; Triamcinolone

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAOCULAR; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 71449091411     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820530903389775     Document Type: Article

References (31)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9.
2. Neelakshi Bhagat, Ruben A. Grigorian, Arthur Tutela, Marco A. Zarbin. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol. 2009:54:1-32.
3. Mark W. Johnson. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147:11-21.
4. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806
5. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results. Ophthalmology. 1991;98:1594-1602
6. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927
7. Maia JR, Takahashi BS,Costa RA, Scott IU, Takahashi WY. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol. 2009;147:291-297
8. Diabetic retinopathy clinical research network ophthalmology a randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-1459
9. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005.
10. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmology. 2007;114:743-750
11. Shimura M, Nakazawa T, Yasuda K.,Shiono T., et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145:854-861
12. Cunningham ET Jr, Adamis AP, Altaweel M, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757
13. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-1696
14. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806-816
15. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: The past, the present, and the future. Surv Ophthalmol. 2008;53:139-149
16. Jonas BJ, Spandau HU, Kamppeter AB, et al. Repeated intravitreal high dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2006;113:800-804
17. Jemark CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503-522
18. Wirostko B, Wong YT, Simo R. Vascular endothelial growth factor and diabetic complications. Progr Retinal Eye Res. 2008;27:608-621
19. Chylak LT Jr, Wolfe JK, Singer Dm, et al. The lens opacities classification system III. The longidutinal study of cataract study group. Arch Ophthalmol. 1993;111:831-836
20. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006;142:794-799
21. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706-1712
22. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501-509
23. Inatani M, Iwao K, Kawaji T, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol. 2008;145:676-681
24. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-1538
25. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse macular oedema: 6 month results of a prospective controlled trial. Acta Ophthalmol Scand. 2006;84:624-630 (Pubitemid 44317541)
26. Marrshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2005;32:S43-7.
27. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmolgy. 2006;113:363-372
28. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483-489
29. Masoud S, Alireza R, Bijan B, et al. Intravitreal Bevacizumab (Avastin) alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Ophthalmic Comm Soc. 2007;27:1187-1195.
30. Spandau UM, Derse M, Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular edema. Ophthalmology. 2005;89:999-1003.
31. Roth DB,Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116: 455-460